SCHEMBL1997620

SCHEMBL1997620

O[C@H]1CC[C@H](Nc2ccnc(-c3cnc4ccc(F)cn34)n2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 5/20 0.52
JAK1 P23458 5/20 0.52
JAK3 P52333 5/20 0.52
MAPK8 P45983 1/20 0.48
MAPK9 P45984 1/20 0.48
EIF2AK4 Q9P2K8 3/20 0.44
MERTK Q12866 1/20 0.43
IRAK4 Q9NWZ3 3/20 0.42
MAPK14 Q16539 3/20 0.41
PIM1 P11309 2/20 0.41
KCNH2 Q12809 2/20 0.41
MKNK1 Q9BUB5 1/20 0.41
LCK P06239 1/20 0.41
RET P07949 1/20 0.41
PDGFRB P09619 1/20 0.41
FLT3 P36888 1/20 0.41
CDK7 P50613 1/20 0.41
BLK P51451 1/20 0.41
IRAK1 P51617 1/20 0.41
CCNH P51946 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1997624 1.00 JAK2 (0.52) JAK2JAK1JAK3MAPK8MAPK9
SCHEMBL12611013 0.87 MAPK8 (0.48) JAK2JAK1JAK3MAPK8MAPK9
SCHEMBL1996185 0.85 IRAK4 (0.58) JAK2JAK1JAK3MAPK8MAPK9
SCHEMBL1996184 0.85 IRAK4 (0.58) JAK2JAK1JAK3MAPK8MAPK9
SCHEMBL2035478 0.84 IRAK4 (0.42) JAK2JAK1JAK3EIF2AK4IRAK4
SCHEMBL2035479 0.84 IRAK4 (0.42) JAK2JAK1JAK3EIF2AK4IRAK4
SCHEMBL1997550 0.83 IRAK4 (0.56) IRAK4LCKRETPDGFRBFLT3
SCHEMBL1997551 0.83 IRAK4 (0.56) IRAK4LCKRETPDGFRBFLT3
SCHEMBL1992660 0.82 IRAK4 (0.58) IRAK4LCKRETPDGFRBFLT3
SCHEMBL1992661 0.82 IRAK4 (0.58) IRAK4LCKRETPDGFRBFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-08-22 US claimed
EP-2338888-A1 Imidazopyridine derivatives as JAK inhibitors Almirall, S.A. (ES) 2011-06-29 EP claimed
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-08-22 US disclosed
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-08-22 US disclosed
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-08-22 US disclosed
EP-2516436-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS Almirall S.A. (ES) 2012-10-31 EP disclosed
WO-2011076419-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2011-06-30 WO disclosed
WO-2011076419-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2011-06-30 WO disclosed
EP-2338888-A1 Imidazopyridine derivatives as JAK inhibitors Almirall, S.A. (ES) 2011-06-29 EP disclosed
EP-2338888-A1 Imidazopyridine derivatives as JAK inhibitors Almirall, S.A. (ES) 2011-06-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS JAK1, JAK2, JAK3 JAK2 2/4885JAK1 1/4885JAK3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.